Document Detail


Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
MedLine Citation:
PMID:  15929107     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Little is known about patterns of hydroxyurea (HU) use by community-based hematologist/oncologists (H/Os) for the treatment of sickle cell disease (SCD). Determination of these practice patterns pertaining to adult SCD patients was the focus of this study. A self-administered survey was mailed to H/Os in two southeastern states. Replies were received from 70% of eligible physicians. This study focuses on responses from 184 community H/Os and a comparison group of 30 university-based/affiliated H/Os providing ongoing care for at least 3 SCD patients/month. The majority of community H/O respondents saw less than 3 SCD patients/month. HU was prescribed by more than half (55%) of community H/Os in at least 10% of their patients. The most common reasons cited for prescribing HU include frequent painful crises (76%), chronic pain with frequent narcotic use (58%), and acute chest syndrome (43%). Although the majority of community H/Os care for few patients with SCD, the reported indications for HU were consistent with currently accepted recommendations. However, community H/Os reported acute chest syndrome, stroke, and pulmonary hypertension as indications for HU less often than the academic H/O group. Barriers to wider use of HU include physician concerns about carcinogenic potential, doubts about HU effectiveness, perceived patient apprehension about adverse effects, concern about lack of contraceptive use, and patient compliance. Further resources should focus on updating physicians on recently published material supporting the effectiveness of HU in symptomatic SCD as well as providing management guidelines to optimize the use of HU.
Authors:
Marc S Zumberg; Suresh Reddy; Robert L Boyette; Robert J Schwartz; Thomas R Konrad; Richard Lottenberg
Related Documents :
18361677 - How the head liberates the heart: projection of communal responsiveness guides relation...
24036027 - Cardiovascular care facts: a report from the national cardiovascular data registry - 2011.
24645127 - Evaluation of the dove centre, phyllis tuckwell hospice, multidisciplinary team meeting...
19919437 - Speech and language therapists as trainers: enabling care staff working with older people.
24748607 - Exchanging care records using hl7 v3 care provision messages.
1702577 - Early diagnosis and referral of children with developmental disabilities.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of hematology     Volume:  79     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-06-06     Completed Date:  2005-08-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  107-13     Citation Subset:  IM    
Affiliation:
Division of Hematology/Oncology, Department of Medicine, University of Florida, Gainesville, Florida 32610-0277, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Sickle Cell / drug therapy*
Antisickling Agents / therapeutic use*
Community Medicine / methods*
Cross-Sectional Studies
Florida
Hematology / methods*
Humans
Hydroxyurea / therapeutic use*
Medical Oncology / methods*
North Carolina
Physician's Practice Patterns*
Questionnaires
Chemical
Reg. No./Substance:
0/Antisickling Agents; 127-07-1/Hydroxyurea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Human parvovirus B19 in patients with aplastic anemia.
Next Document:  Vegetable and fruit consumption and risk of renal cell carcinoma: results from the Netherlands cohor...